2-Ethylcyclopropanmethanol | 62493-33-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Ethylcyclopropanmethanol
• 英文别名: Cyclopropanemethanol, 2-ethyl-, trans-；(2-ethylcyclopropyl)methanol
• CAS: 62493-33-8
• 化学式: C₆H₁₂O
• 分子量: 100.161
• InChiKey: BGKKZLRPGJYFIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  顺-2-戊烯醇 、 bis(iodomethyl)zinc 在 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 以94%的产率得到2-Ethylcyclopropanmethanol
  参考文献：
  名称：

  A new strategy for the Lewis acid-catalyzed cyclopropanation of allylic alcohols.

  摘要：

  DOI：

  10.1021/ja00150a046

文献信息

• Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20070142351A1

  公开（公告）日：2007-06-21

  The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代酰胺衍生物，其显示对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与需要该治疗的患者的多巴胺D3受体活性有关，包括向受试者投予所述化合物的治疗有效量以缓解该疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（如帕金森病、帕金森综合征、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合征和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律障碍和情绪障碍。本发明还涉及制备上述化合物的过程，以及将这些化合物用作多巴胺D3受体成像剂的方法。
• NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS
  申请人：Dong Steven

  公开号：US20130018018A1

  公开（公告）日：2013-01-17

  Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are nucleoside phosphonates and esters thereof.

  本文提供了用于治疗、预防或缓解与病毒感染和/或细胞增殖相关的各种医学疾病的化合物和组合物。此处提供的化合物是核苷酸磷酸酯及其酯类。
• BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
  申请人：Fukuda Yasumichi

  公开号：US20140243302A1

  公开（公告）日：2014-08-28

  Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

  本文披露了新型桥环双环化合物及其药学上可接受的盐、水合物和前药。还披露了包含这些化合物的组合物、制备这些化合物的方法以及将这些化合物用作抗菌剂的方法。披露的化合物、它们的药学上可接受的盐、水合物和前药，以及包含这些化合物、盐、水合物和前药的组合物，可用于治疗细菌感染及相关疾病和病情。
• Compounds for the treatment of bacterial infections
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3050888A1

  公开（公告）日：2016-08-03

  Novel bridged compounds of formula (I) are disclosed herein, along with their pharmaceutically acceptable salts and hydrates. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

  本文公开了式 (I) 的新型桥联化合物及其药学上可接受的盐类和水合物。还公开了包含此类化合物的组合物、制备此类化合物的方法以及将此类化合物用作抗菌剂的方法。所公开的化合物、它们的药学上可接受的盐、水合物和原药，以及包含这些化合物、盐、水合物和原药的组合物，可用于治疗细菌感染及相关疾病和病症。
• METHOD OF FORMING SEMICRYSTALLINE POLYETHERIMIDE, AND POLYETHERIMIDE-CONTAINING COMPOSITION
  申请人：SABIC Global Technologies B.V.

  公开号：EP3741792A1

  公开（公告）日：2020-11-25

  In a method of forming a semicrystalline polyetherimide, a solvent mixture is combined with an amorphous polyetherimide in a weight ratio of 1:1 to 50:1, respectively, to form a first dispersion. The solvent mixture includes dichloromethane and a C1-C6 alkanol in a weight ratio of 0.5:1 to 15:1, respectively. The first dispersion is agitated to form a second dispersion containing a semicrystalline polyetherimide, and the semicrystalline polyetherimide is isolated from the second dispersion. The isolated semicrystalline polyetherimide exhibits a melting point in a range of 230 to 300 °C. Also described is a composition that includes a polyetherimide, dichloromethane, and a C1-C6 alkanol in specific ratios.

  在一种形成半结晶聚醚酰亚胺的方法中，将溶剂混合物与无定形聚醚酰亚胺分别以 1:1 至 50:1 的重量比混合，形成第一分散液。溶剂混合物包括重量比分别为 0.5:1 至 15:1 的二氯甲烷和 C1-C6 烷醇。搅拌第一分散液以形成含有半结晶聚醚酰亚胺的第二分散液，并从第二分散液中分离出半结晶聚醚酰亚胺。分离出的半结晶聚醚酰亚胺的熔点范围为 230 ℃ 至 300 ℃。还描述了一种组合物，该组合物包括特定比例的聚醚酰亚胺、二氯甲烷和 C1-C6 烷醇。